Recommended Hemoglobin Targets for Aranesp
Aranesp (darbepoetin alfa) treats anemia in chronic kidney disease (CKD) patients on dialysis or not on dialysis, and in chemotherapy-induced anemia. The target hemoglobin (Hb) level is 10-11 g/dL. Do not exceed 11 g/dL to minimize risks like stroke, thrombosis, and death.[1][2]
Targets by Patient Group
- CKD patients on dialysis: Initiate Aranesp if Hb <10 g/dL. Titrate to maintain 10-11 g/dL. Reduce or stop dosing if Hb approaches 11 g/dL.[1]
- CKD patients not on dialysis: Same 10-11 g/dL range. Use lowest dose to avoid exceeding 11 g/dL, with slower titration due to less frequent monitoring.[1]
- Chemotherapy-induced anemia: Target 10-12 g/dL in some guidelines, but FDA labeling caps at 11 g/dL maximum, aligning with CKD targets. Reserve for Hb ≤10 g/dL when chemotherapy causes anemia.[1][2]
How Dosing Achieves Targets
Start with 0.45 mcg/kg IV/SC weekly for dialysis CKD, or 0.75 mcg/kg weekly/biweekly for non-dialysis. Adjust by 25% every 4 weeks based on Hb trends: increase if rising <1 g/dL over 4 weeks or <10 g/dL; decrease if >11 g/dL or rising >1 g/dL in 2 weeks. Monitor Hb every 2-4 weeks.[1]
Risks of Higher Targets
Trials like CHOIR (Hb target 13.5 vs 11.3 g/dL) and TREAT (13.5 vs 9 g/dL) showed higher targets increase stroke, hypertension, and vascular events. Normalizing Hb to 12-16 g/dL raises mortality risk, leading to the strict 10-11 g/dL cap.[1][3]
Monitoring and Adjustments
Check Hb twice weekly until stable, then every 2-4 weeks. Hold Aranesp if Hb >11 g/dL; restart at 25-50% lower dose when <10 g/dL. Use iron therapy if ferritin <100 ng/mL or TSAT <20% before or during treatment.[1]
[1]: Aranesp Prescribing Information (Amgen)
[2]: FDA Labeling for Aranesp
[3]: NKF-KDOQI Anemia Guidelines